Related references
Note: Only part of the references are listed.HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
Diu T. T. Nguyen et al.
NATURE COMMUNICATIONS (2020)
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
Gerard Minuesa et al.
NATURE COMMUNICATIONS (2019)
IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation
Sun-Mi Park et al.
CELL STEM CELL (2019)
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
Yang Zhang et al.
RESPIRATORY RESEARCH (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm
Suchita Pakkala et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
EGFR-targeted therapies in the post-genomic era
Mary Jue Xu et al.
CANCER AND METASTASIS REVIEWS (2017)
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets
Alexander E. Kudinov et al.
CLINICAL CANCER RESEARCH (2017)
Stem Cells, Cancer, and MUSASHI in Blood and Guts
Michael G. Kharas et al.
TRENDS IN CANCER (2017)
Handshakes and Fights: The Regulatory Interplay of RNA-Binding Proteins
Erik Dassi
FRONTIERS IN MOLECULAR BIOSCIENCES (2017)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Genome-wide analysis of Musashi-2 targets reveals novel functions in governing epithelial cell migration
Christopher G. Bennett et al.
NUCLEIC ACIDS RESEARCH (2016)
Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis
Alexander E. Kudinov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Masashi Signaling in Stem Cells and Cancer
Raymond G. Fox et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 31 (2015)
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program
Sun-Mi Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor
Nathaniel Hatton et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Natural product (-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1
Lan Lan et al.
MOLECULAR ONCOLOGY (2015)
Transformation of the intestinal epithelium by the MSI2 RNA-binding protein
Shan Wang et al.
NATURE COMMUNICATIONS (2015)
Musashi Protein-directed Translational Activation of Target mRNAs Is Mediated by the Poly( A) Polymerase, Germ Line Development Defective-2
Chad Cragle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs
Sun-Mi Park et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report
Rehan Akbani et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Novel agents in development for advanced non-small cell lung cancer
Thomas E. Stinchcombe
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
Mohamed E. Abazeed et al.
CANCER RESEARCH (2013)
An oxygen-regulated switch in the protein synthesis machinery
James Uniacke et al.
NATURE (2012)
Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: Comparison with manual counting
Zhongli Cai et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2011)
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians
Wei Zhou et al.
Chinese Journal of Cancer (2011)
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
Yun Jung Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
Sergio Iadevaia et al.
CANCER RESEARCH (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Functional proteomic profiling of AML predicts response and survival
Steven M. Kornblau et al.
BLOOD (2009)
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
T. John et al.
ONCOGENE (2009)
Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PABP
Hironori Kawahara et al.
JOURNAL OF CELL BIOLOGY (2008)
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer
Aleksandra Franovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
Takafumi Okabe et al.
CANCER RESEARCH (2007)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
TM4: A free, open-source system for microarray data management and analysis
AI Saeed et al.
BIOTECHNIQUES (2003)
Share Paper
